Compare NTGR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTGR | OCS |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.2M | 417.3M |
| IPO Year | 2000 | 2022 |
| Metric | NTGR | OCS |
|---|---|---|
| Price | $18.60 | $7.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $31.67 | ★ $35.89 |
| AVG Volume (30 Days) | ★ 310.4K | 253.1K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.04 | $389.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.62 | $6.78 |
| 52 Week High | $27.98 | $34.48 |
| Indicator | NTGR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 40.30 |
| Support Level | N/A | $6.95 |
| Resistance Level | $21.99 | $8.84 |
| Average True Range (ATR) | 1.14 | 0.65 |
| MACD | -0.23 | 0.06 |
| Stochastic Oscillator | 16.29 | 33.83 |
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: Enterprise and Consumer which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Home Networking and Mobile offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.